Assessment of Management Lines of Nail Psoriasis: Review Article | ||
| The Egyptian Journal of Hospital Medicine | ||
| Article 256, Volume 91, Issue 1, April 2023, Pages 5409-5414 PDF (522.77 K) | ||
| DOI: 10.21608/ejhm.2023.305753 | ||
| Authors | ||
| Magda Mokhtar Tweer* ; Amany Abdulrahman Nassar; Fathia Mohammed Khattab | ||
| Abstract | ||
| Background: In cases when only the nails are affected by psoriasis, treatment has proven extremely difficult. Psoriatic nail alterations may begin as a Koebner isomorphic reaction to mechanical damage, just as with cutaneous psoriasis. Clinicians should advise patients to take the required safety measures to reduce the risk of the Koebner phenomenon. Gloves and hand lotions can protect hands from harm and encourage short nails. Objective: Review of literature aboutassessment of management lines of nail psoriasis Methods: We searched PubMed, Google Scholar, and Science Direct for relevant articles on nail psoriasis and management. However, only the most recent or thorough study was taken into account between January 2012 and March 2022. The authors also evaluated the value of resources culled from other works in the same genre. Therefore, documents written in languages other than English have been ignored due to a lack of translation funds. Unpublished works, oral presentations, conference abstracts, and dissertations were generally agreed upon not to qualify as scientific research. Conclusion: In cases when only the nails are affected by psoriasis, treatment has proven extremely difficult. The major causes of this problem are the sluggish growth rate of the nails and the low penetration of topical drugs. Treatment options such as etanercept, intralesional corticosteroids, ustekinumab, acitretin, methotrexate sodium, and adalimumab are suggested for patients with severe nail disease that has not responded to topical medication. Ustekinumab, adalimumab as well as etanercept, are highly advised for people with severe skin and nail disorders. Also, methotrexate, acitretin, infliximab, and apremilast are suggested. | ||
|
Statistics Article View: 173 PDF Download: 402 |
||
